Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Pierluigi Porcu"'
Autor:
Laura Gleason, Volkan Tekmen, Alexa Cohen, Safiyyah Bhatti, Burcu Beksac, Jisun Cha, Pierluigi Porcu, Neda Nikbakht
Publikováno v:
International Journal of Dermatology and Venereology.
Autor:
Michael Chang, Pierluigi Porcu, Li-Anne S Lim, Arman Mashayekhi, Lauren A Dalvin, Nina L. Martinez, Mehdi Mazloumi, Carol L. Shields, David Ancona-Lezama, Jon Glass
Publikováno v:
Asia-Pacific Journal of Ophthalmology. 9:110-116
Purpose The aim of this study was to identify clinical factors predictive of time to central nervous system (CNS) lymphoma or death in patients with vitreoretinal lymphoma (VRL). Design Retrospective cohort study. Methods Patients with VRL (n = 95 pa
Autor:
Adam F. Binder, Pierluigi Porcu
Publikováno v:
Oncology Times. 40:1-17
Autor:
Rein Willemze, Christiane Querfeld, Joya Pawade, Melissa Pulitzer, Michael T. Tetzlaff, Jinah Kim, Laura B. Pincus, Lorenzo Cerroni, E. Hong, Pierluigi Porcu, Maxime Battistella, Werner Kempf, Bethany Horton, David J. DiCaudo, Youn H. Kim, Aaron R. Mangold, Joan Guitart, Julia Scarisbrick, Alejandro A. Gru, Andras Schaffer, Gary S. Wood, Madeleine Duvic, Michi Shinohara
Publikováno v:
Am J Surg Pathol
This pathology PILOT study aims to define the role and feasibility of centralized pathology review in a cohort of 75 patients from different centers in the United States and Europe using digital slide scanning. The pathologic material from 75 patient
Autor:
Stanley I. Martin, Robert A. Baiocchi, Carl Quinion, Mark E. Lustberg, Susan Geyer, Ronald P. Pelletier, Pierluigi Porcu, Michael A. Caligiuri
Publikováno v:
Transplantation. 99:1220-1225
Posttransplant lymphoproliferative disorder (PTLD) is an infrequent but serious complication of solid organ transplantation. Early detection and initiation of therapy may improve outcomes. The purpose of this study was to identify human leukocyte ant
Publikováno v:
Current Opinion in Oncology. 15:353-362
PURPOSE OF REVIEW: T-cell/natural killer (T/NK)-cell lymphomas represent a group of poor-risk lymphoproliferative disorders that have only recently been recognized as distinct clinicopathologic entities. The average outcome with currently available t